Niagen Bioscience (NAGE) Liabilities from Discontinued Operations (2016)
Niagen Bioscience (NAGE) reported Liabilities from Discontinued Operations of 184766.0 for Q4 2016.
Niagen Bioscience (NAGE) Liabilities from Discontinued Operations (2016) Analysis & Trends
Niagen Bioscience (NAGE) has 1 years of Liabilities from Discontinued Operations data on file, last reported at 184766.0 in Q4 2016.
- Liabilities from Discontinued Operations for Q4 2016 came in at 184766.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2016 was 184766.0 (changed N/A YoY), and the FY2016 annual result was 184766.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations was little changed at 184766.0 in Q4 2016 per NAGE's latest filing.
- Over five years, Liabilities from Discontinued Operations peaked at 184766.0 in Q4 2016 and troughed at 184766.0 in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Niagen Bioscience | 269.32 Mn | 202.77 Mn | 19.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 184,766.00 |
| Dec 31, 2016 | 184,766.00 |